I am a clinical academic with a primary interest in schizophrenia and psychosis. I trained in Barcelona (Spain) in 2003 and moved to Cambridge in 2007. Since 2011, I lead the chronic schizophrenia team and, since 2021, the Cambridge Psychosis Centre, a regional second opinion unit. From 2025, I am assistant Professor at the Department of Psychiatry, University of Cambridge.
My PhD was on the neuroscience of emotion recognition in schizophrenia, and then I explored the idea of schizophrenia as a whole-body disease. I recently focused on investigating factors associated with comorbidity in schizophrenia and how it reflects on the concept of schizophrenia also via the study of negative symptoms and clozapine-induced checking. We have conducted commercial and non-commercial clinical trials and collaborations within UoC, UK centres and abroad.
My research received funding from, among others, NARSAD, NIH (RO1), NIHR-BRC and NIHR-HTA. In addition, I had a number of awards and prizes for my clinical work (Clinical Excellent Awards), training, PhD, and research. Full list of publications and research lines can be seen in the website.
-
Assistant Professor. Department of Psychiatry. University of Cambridge
Consultant Psychiatrist – Cambridgeshire and Peterborough NHS Foundation Trust.
Mental Health Consultant - Exceptional -Individual Funding Requests. ICB Cambridgeshire
Director, Cambridge Psychiatry Ltd.
-
1997 MBBS Bachelor Medicine, Universidad Autonoma Barcelona, Spain.
2003 CCT/MD Specialist in Psychiatry, Hospital Clinic, Barcelona, Spain
2006 DStat in Statistics for Health Science. Universidad Autonoma Barcelona, Spain.
2010 PhD in Neuroscience, Universidad de Barcelona, Spain.
2022 MA (Cantab) Master of Arts (teaching).
-
Deputy Editor, British Journal of Psychiatry
Associate Editor, Spanish Journal of Psychiatry and Mental Health
Committee member, International HTA, NIHR
Chair, International scientific committee CIBERSAM
ECNP - Schizophrenia theme
TRIPP - member
-
2021 – European Psychiatric Association (EPA) [EPA03683]
2020 – British Association for Psychopharmacology (BAP).
2018 – European College Neuropsychopharmacology (ECNP).
2018 – Accredited University lecturer by the Spanish Agency for Academic Quality (ANECA).
2018 – Accredited University lecturer by the Catalan Agency for University Quality (AQU).
2011 – Specialist Associate of the Royal College of Psychiatrists (College Number: 826447)
2007 – Sociedad Española Psiquiatría (SEP) – Reference Researcher (2023 -)
2007 – General Medical Council (6162903) – Specialist Register – Revalidated 2016 & 2022 (until 14/02/2027).
2006 – Schizophrenia International Research Society (SIRS) [SIRS5007203]
-
2021-23 – NABEN for clozapine resistant schizophrenia cases. Top UK recruiter.
2011-2012 – PATTERN (Roche) for treatment resistant schizophrenia. Top UK recruiter.
-
The life of an academic clinician is full of conflict of interest. We all sit in boards and committees, have collaborators and students and are almost inevitably involved with industry. It is not an easy balance, which requires transparency, fairness and strict ethical principles.
I am particularly keen to offer full transparency about my activity. Here is the list of paid and unpaid roles and potential conflict of interest, current or over last 4 years
Below is the disclaimer in my publications
Conflict of interest. EFE has received consultancy honoraria from Boehringer-Ingelheim (2022), Atheneum (2022) and Rovi (2022-24), speaker fees from Adamed (2022-25), Otsuka (2023) and Viatris (2024) and editorial honoraria from Spanish Society of Psychiatry and Mental Health (2023-2025).
Funding. Dr Fernandez-Egea is supported by the 2022 MRC/NIHR CARP award (MR/W029987/1) and All research at the Department of Psychiatry in the University of Cambridge is supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the NIHR Applied Research Collaboration East of England. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.